Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

D.Western Therapeutics Institute (4576) Stock Price & Analysis

4576 Stock Chart & Stats

¥59.00-¥2.00(-3.28%)
At close: 3:30 PM GMT+9
JPY 60JPY 70JPY 80JPY 903 Aug17 Aug31 Aug14 Sep28 Sep13 Oct26 Oct
Day’s Range
JPY 59.00 - JPY 61.00
52-Week Range
JPY 59.00 - JPY 111.00
Previous Close
JPY 61.00
Volume
3.18M
Average Volume (3M)
248.74K
Market Cap
JPY 3.40B
Enterprise Value
JPY 3.25B
Total Cash (Recent Filing)
JPY 1.54B
Total Debt (Recent Filing)
JPY 594.17M
Price to Earnings (P/E)
―
Beta
-0.18
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Gross Margins

Very strong gross margins indicate that the company’s underlying drug-related activities can retain substantial value after direct costs. If revenue stabilizes and operating expenses become better aligned with scale, this gross-profit profile could support meaningful earnings improvement over the next several quarters.

Narrowing Losses

The improvement in losses shows progress toward reducing the gap between operating expenses and revenue, even though profitability remains negative. Continued cost or development discipline could extend this trend, improving financial resilience and making future funding needs more manageable.

Improved Leverage

The substantial reduction in debt-to-equity strengthens the company’s balance-sheet position relative to the prior year and reduces leverage-related pressure. A healthier capital structure can provide greater flexibility to sustain research programs and manage ongoing losses while pursuing development opportunities.

Bears Say

Persistent Cash Burn

Persistent negative operating and free cash flow means the business does not currently fund its activities internally. Continued cash burn can require additional financing or capital support, potentially limiting strategic flexibility and increasing the importance of successful development progress.

Deep Unprofitability

Net losses exceeding revenue demonstrate that the company remains far from break-even despite its strong gross margin and improved results. Sustained operating and net losses can consume equity, constrain reinvestment capacity, and delay the point at which the business becomes financially self-sustaining.

Weak Revenue Trend

Small, volatile, and declining revenue makes it harder for the company to absorb fixed research and operating costs. Without a durable return to growth, the strong gross margin may not translate into improved earnings, while dependence on external funding could remain elevated.

D.Western Therapeutics Institute News

4576 FAQ

What was D.Western Therapeutics Institute’s price range in the past 12 months?
D.Western Therapeutics Institute lowest stock price was ¥59.00 and its highest was ¥111.00 in the past 12 months.
What is D.Western Therapeutics Institute’s market cap?
D.Western Therapeutics Institute’s market cap is ¥3.40B.
When is D.Western Therapeutics Institute’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were D.Western Therapeutics Institute’s earnings last quarter?
D.Western Therapeutics Institute released its earnings results on Aug 13, 2026. The company reported -¥2.66 earnings per share for the quarter.
Is D.Western Therapeutics Institute overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does D.Western Therapeutics Institute pay dividends?
D.Western Therapeutics Institute does not currently pay dividends.
What is D.Western Therapeutics Institute’s EPS estimate?
D.Western Therapeutics Institute’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute have?
D.Western Therapeutics Institute has 57,599,410 shares outstanding.
What happened to D.Western Therapeutics Institute’s price movement after its last earnings report?
D.Western Therapeutics Institute reported an EPS of -¥2.66 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute?
Currently, no hedge funds are holding shares in JP:4576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology